Launch One Acquisition Corp. LPAA
- Market cap
- $81.3M
- P/E
- —
Follow LPAA
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 9.66 | 10.04 | 10.59 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 10.05 | 10.70 | 11.67 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Launch One Acquisition Corp. peers in Shell Companies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IMAQ International Media Acquisition Corp. | $81.2M | 0.0× | Compare |
| PRLH Pearl Holdings Acquisition Corp. | $81.2M | 33.3× | Compare |
| TGAAF Target Global Acquisition I Corp. | $81.1M | 38.0× | Compare |
| WSTN Westin Acquisition Corp. | $81.9M | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| APAC StoneBridge Acquisition II Corporation | $82.7M | — | Compare |
| TCOA Zalatoris Acquisition Corp. | $79.2M | 61.8× | Compare |
| ISRLF Israel Acquisitions Corp. | $78.8M | 56.9× | Compare |
| WELNF Integrated Wellness Acquisition Corp. | $83.9M | 81.4× | Compare |
Launch One Acquisition Corp. (LPAA) Latest News
13 Jan
Minovia Therapeutics has been granted two new U.S. patents that enhance its mitochondrial augmentation therapy platform, which aims to treat mitochondrial diseases. These patents are expected to strengthen the company's intellectual property position and support its ongoing development efforts in innovative therapies. The new patents are likely to significantly enhance Minovia's competitive positioning and investor sentiment regarding its therapeutic advancements.
Minovia Therapeutics has been granted two new U.S. patents that enhance its mitochondrial augmentation therapy platform. These patents are expected to bolster the company's intellectual property portfolio and support its ongoing development of innovative treatments for mitochondrial diseases. The new patents signify a strategic advancement in Minovia's efforts to address unmet medical needs in this area. The new patents significantly strengthen Minovia's competitive position and could lead to major advancements in its product offerings.
20 Nov
Minovia Therapeutics will showcase its Mitochondrial Augmentation Technology at the 67th ASH Annual Meeting and Exposition, highlighting its potential in treating mitochondrial diseases. The presentation aims to inform attendees about advancements in this innovative approach, which could lead to significant developments in the field of regenerative medicine. The presentation of innovative technology may influence Minovia's competitive positioning and market sentiment, but its overall effect on Launch One Acquisition Corp. is expected to be limited.
15 Oct
Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome. Orphan Drug Designation advances MNV-201 development and may lift near-term sentiment for Launch One Acquisition Corp. as the linked entity.
Minovia Therapeutics has received FDA Orphan Drug Designation for its product MNV-201, aimed at treating Myelodysplastic Syndrome (MDS). This designation is intended to facilitate the development of therapies for rare diseases, providing Minovia with potential benefits such as tax credits and market exclusivity upon approval. The FDA designation may enhance Minovia's competitive positioning and financial performance in the niche market of MDS treatments.
18 Sep
Minovia Therapeutics has received FDA Fast Track Designation for its product MNV-201, aimed at treating Myelodysplastic Syndrome. This designation is intended to expedite the development and review process for drugs that address unmet medical needs, potentially allowing for quicker access to the treatment for patients. The FDA Fast Track Designation could significantly enhance Minovia Therapeutics' market position and investor sentiment regarding its product pipeline.
Minovia Therapeutics, merging with Launch One Acquisition Corp. (LPAA), received FDA Fast Track Designation for MNV-201 to treat Myelodysplastic Syndrome. FDA Fast Track Designation accelerates Minovia's MDS therapy development, significantly boosting LPAA's biotech merger value and investor sentiment.
27 Aug
Minovia Therapeutics has received a $350,000 grant from the Countdown for a Cure Foundation to develop blood-based biomarkers related to mitochondria. This funding aims to advance research in mitochondrial diseases, potentially leading to improved diagnostics and treatments. The grant may enhance Minovia's research capabilities and product development, which could positively influence LPAA's investment in the company.
24 Jul
Minovia Therapeutics has announced interim data from its Phase 2 trial for Pearson Syndrome, revealing no treatment-related serious adverse events and a preliminary signal for efficacy indicated by patient growth metrics. The trial results may influence investor sentiment and the company's competitive positioning in the biotech sector.
30 Jun
Minovia Therapeutics has received FDA Fast Track and Rare Pediatric Disease Designations for its investigational compound MNV-201, aimed at treating Pearson Syndrome, a severe mitochondrial disorder in children. These designations will expedite the development and review process, potentially leading to a quicker market entry. Minovia is currently conducting a Phase 2 clinical trial for MNV-201 and plans to initiate pivotal trials in 2026. Additionally, Minovia has entered a business combination agreement with Launch One Acquisition Corp., expected to close in late 2025, after which the combined entity will operate under a new Nasdaq ticker symbol. The FDA designations and upcoming business combination are significant strategic moves that could greatly enhance Minovia's market position and investor sentiment.
25 Jun
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. have announced a proposed business combination to create a publicly traded biotechnology company focused on mitochondrial therapies. The merger aims to leverage Minovia's Mitochondrial Augmentation Technology (MAT) to address diseases caused by mitochondrial dysfunction. The combined entity, named Mito US One Ltd., is expected to be listed on Nasdaq and will utilize approximately $239.7 million in cash from Launch One's trust account to accelerate Minovia's growth and development pipeline. The transaction is anticipated to close in Q4 2025, pending shareholder approvals. The business combination is expected to significantly enhance Minovia's market position and funding for its innovative therapies, impacting future performance.